Phagos uses an AI-driven platform to discover and engineer bacteriophages that precisely target bacterial pathogens in livestock and aquaculture, offering antibiotic‑free treatments that preserve beneficial microbes. The company provides species‑specific phage cocktails and continuously updates formulations to stay effective against evolving antimicrobial resistance.
Funding
$29M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bacterial infections in livestock are a major cause of mortality and economic loss, and the effectiveness of traditional antibiotics is declining due to rising antimicrobial resistance (AMR).
Solution
Phagos leverages an AI-native platform, Alphagos, to discover and engineer bacteriophages that specifically target pathogenic bacteria in animals such as chickens, cattle, swine, and shrimp. By isolating natural phages from the environment and applying machine‑learning models, the platform rapidly identifies candidates with high specificity and potency. Engineered phage cocktails are formulated as antibacterial medicines that kill target bacteria while leaving beneficial microbes untouched. Continuous updates to the phage formulations allow the treatments to stay effective as bacterial populations evolve, providing a sustainable, non‑antibiotic alternative for disease control in animal agriculture.
Target Audience
Primary customers are livestock producers and veterinary pharmaceutical companies seeking targeted, antibiotic‑free solutions for bacterial disease management in poultry, cattle, swine, and aquaculture.
Features
- AI-driven pipeline that screens environmental phage libraries to match specific bacterial pathogens
- Precision engineering of phage genomes to enhance efficacy and broaden host range
- Species‑specific phage formulations for poultry, cattle, swine, and shrimp applications
- Continuous formulation updates to counter emerging antimicrobial resistance
- Scalable production process compatible with existing veterinary delivery methods